<DOC>
	<DOC>NCT01206361</DOC>
	<brief_summary>The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.</brief_summary>
	<brief_title>Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Patients who had received a prescription for either Xalacom, Ganfort and DuoTrav Greater than 18 years old Diagnosed with glaucoma or ocular hypertension Registered at the primary care practice for &gt; 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Real world</keyword>
	<keyword>observational</keyword>
	<keyword>retrospective</keyword>
	<keyword>database analysis</keyword>
</DOC>